The new microfluidic chip is designed to capture more circulating tumor cells in patients with non-small cell lung cancer than currently available technologies.
The firm hopes that Medicare coverage will facilitate patient access to the NavDx test and spur its inclusion in practice guidelines for head and neck cancer.
At AACR, a study explored the impact of a chain of default notifications in prompting physician referrals and patient adoption of genetic testing in colorectal cancer patients.
UPitt is hoping the latest data demonstrating the utility of its 22-gene PancreaSeq test will help drive adoption and reimbursement.
The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.